DOCSLIB.ORG

Pseudoproline Dipeptides Pseudoprolindipeptide Dipeptides De Pseudoproline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pseudoproline Dipeptides Pseudoprolindipeptide Dipeptides De Pseudoproline (19) TZZ ¥_6B_T (11) EP 2 344 516 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 1/02 (2006.01) C07K 5/06 (2006.01) 20.03.2013 Bulletin 2013/12 C07K 5/062 (2006.01) C07D 263/06 (2006.01) (21) Application number: 09783513.6 (86) International application number: PCT/EP2009/062568 (22) Date of filing: 29.09.2009 (87) International publication number: WO 2010/040660 (15.04.2010 Gazette 2010/15) (54) Pseudoproline dipeptides Pseudoprolindipeptide Dipeptides de pseudoproline (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR WO-A-00/46239 WO-A-2008/000641 HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR • TORSTEN WÖHR ET AL: "Pseudo-Prolines as a Solubilizing, Structure-Disrupting Protection (30) Priority: 07.10.2008 EP 08165968 Technique in Peptide Synthesis" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (43) Date of publication of application: AMERICAN CHEMICAL SOCIETY, 20.07.2011 Bulletin 2011/29 WASHINGTON,DC. US, vol. 118, no.39, 2 October 1996 (1996-10-02), pages 9218-9227, (73) Proprietor: F. Hoffmann-La Roche AG XP002447320 ISSN: 0002-7863 cited in the 4070 Basel (CH) application • WOHR T ET AL: "Pseudo-Prolines in Peptide (72) Inventor: HILDBRAND, Stefan Synthesis: Direct Insertion of Serine and CH-4460 Gelterkinden (CH) Threonine Derived Oxazolidines in Dipeptides" TETRAHEDRON LETTERS, ELSEVIER, (74) Representative: Rauber, Beat AMSTERDAM, vol. 36, no. 22, 29 May 1995 F.Hoffmann-La Roche AG (1995-05-29), pages 3847-3848, XP004027998 Patent Department ISSN: 0040-4039 675 / 3. OG Grenzacherstrasse 4070 Basel 2 (CH) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 344 516 B1 Printed by Jouve, 75001 PARIS (FR) EP 2 344 516 B1 Description [0001] The invention relates to a novel process for the manufacture of a compound of the formula 5 10 [0002] The pseudo proline dipeptides of formula I can be used as reversible protecting groups for Ser, Thr, and Cys and prove to be versatile tools for overcoming some intrinsic problems in the field of peptide chemistry [JACS 1996, 15 118, 9218-9227]. The presence ofΨ Pro within a peptide sequence results in the disruption ofβ-sheet structures considered as a source of intermolecular aggregation. The resulting increased solvation and coupling kinetics in peptide assembly such as Fmoc solid phase peptide synthesis facilitates chain elongation especially for peptides containing "difficult sequences". [0003] A synthetic approach to pseudoproline dipeptides is published in PCT Publication WO 2008/000641. Access 20 to the compound of formula I is accomplished via an ammonium salt intermediate of formula 25 30 wherein R1, R2, R5,R6, R7 and R8 are defined in the PCT Publication mentioned above. [0004] One major disadvantage of the approach known in the art is the need to purify the dipeptide by isolation of its ammonium salt intermediate, which prior to the ring closure has to be liberated to the dipeptide. Accordingly this synthesis turned out not to be suitable for the application on a technical scale. [0005] Object of the present invention is to provide a short and technically feasible synthesis of the pseudo proline 35 dipeptides of formula I which allows for obtaining the product with a high yield. [0006] The object has been achieved with the process as outlined below. The process for the manufacture of a compound of formula 40 45 wherein R1 is a side chain of an alpha amino acid, R2 is an amino protecting group and R3 and R are independently 3 4 5 selected from hydrogen or C1-4 alkyl with the proviso that not both R and R are hydrogen R is hydrogen or methyl comprising 50 a) converting an amino acid derivative of the formula 55 2 EP 2 344 516 B1 wherein R1 and R2 are as above, with serine or threonine into the dipeptide of formula 5 10 thereby using a water soluble carbodiimide as activating agent and b) effecting the ring closure of the dipeptide of formula III with a compound of formula 15 20 3 4 wherein R and R are independently selected from hydrogen or C1-4-alkyl, with the 3 4 9a 9b proviso that not both R and R are hydrogen and R and R independently is C1-4-alkyl, in the presence of an acidic catalyst, wherein the target compound of formula I is obtained by a work up procedure comprising a) extracting the reaction mixture with water, while maintaining a pH in the range of 7.0 to 9.0; 25 b) extracting the water phase with an organic, water immiscible solvent, while maintaining a pH in the range of 5.5 to 6.0; c) obtaining the target product of formula I from the organic phase and optionally by d) crystallizing the target product of formula I in an organic solvent. 30 [0007] It is further understood that the serine or threonine can be used either in its L- or in their D-configuration, as racemate or in various mixtures of their isomers. Preferably the L-configuration is used. [0008] The term "C 1-4- alkyl" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to four carbon atoms. This term is further exemplified by radicals as methyl, ethyl, n-propyl, isopropyl, n- butyl, s- butyl and t-butyl. 35 [0009] The term "side chain of an amino acid" used for the substituent R 1 particularly refers to side chains of the alpha amino acids selected from valine, leucine, isoleucine, methionine, phenylalanine, asparagine, glutamine, glutamic acid, histidine, lysine, arginine, aspartic acid, alanine, serine, threonine, tyrosine, tryptophan, cysteine, glycine, aminoisobutyri c acid and proline. [0010] It is understood that in side chains of amino acids which carry a hydroxy group the hydroxy group is optionally 40 protected by a hydroxy protecting group as defined below. In side chains that carry additional amino groups the amino group is optionally protected by an amino protecting group as defined below. [0011] R1 preferably stands for a side chain of valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, glutamic acid, lysine, aspartic acid, alanine, serine, threonine, tyrosine and tryptophan. In a more preferred embodiment R1 stands for a side chain of serine or threonine. 45 [0012] The term "amino protecting group" refers to any substituents conventionally used to hinder the reactivity of the amino group. Suitable amino protecting groups are described in Green T., "Protective Groups in Organic Synthesis", Chapter 7, John Wiley and Sons, Inc.,1991, 309-385. Suitable amino protecting groups as defined under R2 should withstand under acidic conditions. Preferably Fmoc, Z, Moz, Troc, Teoc or Voc more preferably Fmoc is used. [0013] The term "hydroxy protecting group" refers to any substituents conventionally used to hinder the reactivity of 50 the hydroxy group. Suitable hydroxy protecting groups are described in Green T., "Protective Groups in Organic Syn- thesis", Chapter 1, John Wiley and Sons, Inc.,1991, 10-142. Suitable hydroxy protecting groups are t-butyl, benzyl, TBDMS or TBDPS. Preferred hydroxy protecting group is t-butyl. [0014] The meaning of the abbreviations used in the description and the claims is as outlined in the table below: 55 Fmoc 9-Fluorenylmethoxycarbonyl Z Benzyloxycarbonyl 3 EP 2 344 516 B1 (continued) Fmoc 9-Fluorenylmethoxycarbonyl tBu t-butyl 5 Moz p-Methoxybenzyloxycarbonyl Troc 2,2,2-Trichloroethoxycarbonyl Teoc 2-(Trimethylsilyl)ethoxycarbonyl 10 Voc Vinyloxycarbonyl TBDMS t-Butyldimethylsilyl ether TBDPS t-Butyldiphenylsilyl ether HOBt 1-Hydroxybenzotriazole 15 HOSu N-Hydroxysuccinimide EAC 1-Ethyl-3-(4-azonia-4,4-dimethylpentyl)-carbodiimide (iodide) EDC (3-Dimethylamino-propyl)-ethyl-carbodiimide (hydrochloride) 20 Step a) [0015] In the first step a) the amino acid derivative of formula 25 30 wherein R1 and R2 are as above is converted with serine or threonine into the dipeptide of formula 35 40 thereby using a water soluble carbodiimide as activating agent. [0016] The amino acid derivatives of formula II are as a rule commercially available compounds. Suitable amino acid derivatives of formula II according to the preferences given for R1 and R2 are Fmoc-L-Ser (tBu)-OH, or Fmoc-L-Thr (tBu)-OH. 45 [0017] Suitable water soluble carbodiimide activating agents are EDC or EAC or salts thereof, preferably the hydro- chloride salt of EDC. [0018] As a rule the water soluble carbodiimide activating agent is applied together with a further activating agent selected from HOSu or HOBt. [0019] Preferred activating agent is EDC.HCl/HOSu. 50 [0020] The EDC is usually applied in an amount of 1.0 to 1.5 equivalents and the HOSu is usually applied in an amount of 1.0 to 1.5 equivalents related to one equivalent of the amino acid derivative of formula II. [0021] As a rule the activation reaction is performed in the presence of a suitable organic solvent, such as ethylacetate, N, N-dimethylformamide, acetone or tetrahydrofuran, preferably tetrahydrofuran and / or N, N-dimethylformamide at a temperature of -10°C to 25°C. 55 [0022] The coupling with serine or threonine, preferably with L-serine or L-threonine, can then be performed at a temperature of -10°C to 25°C in the presence of an inorganic base.
Load more

Recommended publications
  • A Global Review on Short Peptides: Frontiers and Perspectives †
    molecules Review A Global Review on Short Peptides: Frontiers and Perspectives † Vasso Apostolopoulos 1 , Joanna Bojarska 2,* , Tsun-Thai Chai 3 , Sherif Elnagdy 4 , Krzysztof Kaczmarek 5 , John Matsoukas 1,6,7, Roger New 8,9, Keykavous Parang 10 , Octavio Paredes Lopez 11 , Hamideh Parhiz 12, Conrad O. Perera 13, Monica Pickholz 14,15, Milan Remko 16, Michele Saviano 17, Mariusz Skwarczynski 18, Yefeng Tang 19, Wojciech M. Wolf 2,*, Taku Yoshiya 20 , Janusz Zabrocki 5, Piotr Zielenkiewicz 21,22 , Maha AlKhazindar 4 , Vanessa Barriga 1, Konstantinos Kelaidonis 6, Elham Mousavinezhad Sarasia 9 and Istvan Toth 18,23,24 1 Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia; [email protected] (V.A.); [email protected] (J.M.); [email protected] (V.B.) 2 Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland 3 Department of Chemical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Kampar 31900, Malaysia; [email protected] 4 Botany and Microbiology Department, Faculty of Science, Cairo University, Gamaa St., Giza 12613, Egypt; [email protected] (S.E.); [email protected] (M.A.) 5 Institute of Organic Chemistry, Faculty of Chemistry, Lodz University of Technology, Zeromskiego˙ 116, 90-924 Lodz, Poland; [email protected] (K.K.); [email protected] (J.Z.) 6 NewDrug, Patras Science Park, 26500 Patras, Greece; [email protected] 7 Department of Physiology and Pharmacology,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0082079 A1 Spetzler Et Al
    US 2011 0082079A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0082079 A1 Spetzler et al. (43) Pub. Date: Apr. 7, 2011 (54) GLUCAGON-LIKE PEPTDE-1 DERVATIVES Publication Classification AND THEIR PHARMACEUTICAL USE (51) Int. Cl. A638/22 (2006.01) (75) Inventors: Jane Spetzler, Bronsho (DK); C07K I4/575 (2006.01) Lauge Schäffer, Lyngby (DK); A6IP3/10 (2006.01) Jesper Lau, Farum (DK); Thomas A6IP 9/12 (2006.01) Kruse, Herlev (DK); Patrick A6IP3/04 (2006.01) William Garibay, Holte (DK); A6IP 9/10 (2006.01) Steffen Runge, Frederiksberg A6IPI/00 (2006.01) (DK); Henning Thogersen, Farum A6IPL/04 (2006.01) (DK); Ingrid Petersson, Frederiksberg (DK) (52) U.S. Cl. .......................... 514/7.2:530/399; 514/11.7 (57) ABSTRACT (73) Assignee: Novo Nordisk A/S, Bagsvard (DK) The invention relates to protracted Glucagon-Like Peptide-1 Appl. No.: (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 (21) 12/676,451 derivative of the invention comprises a modified GLP-1 (7- PCT Fled: 37) sequence having a total of 2-12 amino acid modifications, (22) Sep. 5, 2008 including Glu22 and Arg26, and being derivatised with an PCT NO.: PCT/EP2008/061755 albumin binding residue or pegylated in position 18, 20, 23. (86) 30, 31, 34, 36, 37, or 39. These compounds are useful in the S371 (c)(1), treatment or prevention of diabetes type 2 and related dis (2), (4) Date: Oct. 13, 2010 eases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of (30) Foreign Application Priority Data binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall Sep.
    [Show full text]
  • PYY(3-36) Analogues: Structure
    PYY(3-36) analogues: Structure- activity relationships in energy homeostasis A thesis submitted for the degree of Doctor of Philosophy, Imperial College London 2011 Iain David Pritchard Section of Investigative Medicine Division of Diabetes, Endocrinology and Metabolism Department of Medicine Imperial College London Abstract The developed world is currently in the grip of an obesity epidemic. As a result, there is much ongoing research into the development of an effective anti-obesity agent. Peptide YY (PYY) is a 36 amino acid gastro-intestinal hormone released post- prandially by L-cells in the gastro-intestinal tract in proportion to the calorie content of a meal. The predominant form of the hormone found in circulation is the truncated PYY(3-36). Administration of PYY(3-36) at physiological doses to humans has been shown to reduce food intake. However, due to enzymatic degradation these effects are short lived, reducing the hormone’s utility as an anti-obesity pharmaceutical agent. A series of analogues of PYY(3-36) were designed either with amino acid substitutions in specific parts of the peptide sequence and/or with chemical modifications to the native sequence with the aim of increasing resistance to enzymatic activity whilst retaining or even enhancing the peptide’s bioactivity. The analogues were tested for resistance to degradation by different proteolytic enzymes in comparison to natural PYY(3-36). Their affinity to the Y2 receptor, for which PYY(3-36) is a natural agonist was then investigated. Finally, the effects of peripheral administration of selected analogues on food intake in overnight fasted mice were investigated.
    [Show full text]
  • Peptides As Therapeutics with Enhanced Bioactivity
    Send Orders of Reprints at [email protected] Current Medicinal Chemistry, 2012, 19, 4451-4461 4451 Peptides As Therapeutics with Enhanced Bioactivity D. Goodwin1, P. Simerska1 and I. Toth*,1,2, 1The University of Queensland, School of Chemistry and Molecular Biosciences; 2School of Pharmacy, St. Lucia 4072, Queensland, Australia Abstract: The development of techniques for efficient peptide production renewed interest in peptides as therapeutics. Numerous modi- fications for improving stability, transport and affinity profiles now exist. Several new adjuvant and carrier systems have also been developed, enhancing the immunogenicity of peptides thus allowing their development as vaccines. This review describes the established and experimental approaches for manufacturing peptide drugs and highlights the techniques currently used for improving their drug like properties. Keywords: Peptide, drug delivery, vaccine, manufacture, bioavailability, peptide therapeutic, immunogenicity, peptide drug, peptide synthe- sis, clinical trials. INTRODUCTION side-chain reactivity, degree of modification, incorporation of un- natural components, in addition to the required purity, solubility, Natural and synthetic peptides have shown promise as pharma- stability and scale. There are two strategies for peptide production - ceutics with the potential to treat a wide variety of diseases. This chemical synthesis and biological manufacturing. potential is often overshadowed by the inability of the peptides to reach their targets in an active form in vivo. The delivery of active Chemical Peptide Synthesis peptides is challenging due to inadequate absorption through the Chemical synthesis has been used for the production of peptides mucosa and rapid breakdown by proteolytic enzymes. Peptides are in both research and industry and led to the development of the usually selective and efficacious, therefore need only be present in majority of peptide drugs [2].
    [Show full text]
  • 1 Peptide Therapeutics
    Universal Free E-Book Store Donate Us, In order to keep our Service Alive, We have to pay for placing files (Abstracts, Books, Literature & Software) on File Hosting Servers, Your donations will make our process of payment a bit easier, Please use any one of the Payment Gateway for Donation. Never matter what amount you donate (10’s or 100’s or 1000’s). Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Universal Free E-Book Store Universal Free E-Book Store PEPTIDE CHEMISTRY AND DRUG DESIGN Edited by BEN M. DUNN Universal Free E-Book Store Copyright © 2015 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permissions. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose.
    [Show full text]
  • Conformations of Heterochiral and Homochiral Proline-Pseudoproline
    Conformations of Heterochiral and Homochiral Proline-Pseudoproline ConformationsSegments in of Peptides: Heterochiral Context and Dependent HomochiralCis–Trans Proline-PseudoprolinePeptide SegmentsBond Isomerization in Peptides: Context Dependent Cis–Trans Peptide Bond Isomerization Kantharaju,1 Srinivasarao Raghothama,2 Upadhyayula Surya Raghavender,3 Subrayashastry Aravinda,3 Narayanaswamy Shamala,3 Padmanabhan Balaram1 1 Molecular Biophysics Unit, Indian Institute of Science, Bangalore, Karnataka 560012, India 2 NMR Research Centre, Indian Institute of Science, Bangalore, Karnataka 560012, India 3 Department of Physics, Indian Institute of Science, Bangalore, Karnataka 560012, India Received 9 March 2009; accepted 7 April 2009 Published online 16 April 2009 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/bip.21207 ABSTRACT: stabilized by two intramolecular hydrogen bonds. Further truncation of the sequence gives an appreciable rise in the The pseudoproline residue (CPro, L-2,2-dimethyl-1,3- D thiazolidine-4-carboxylic acid) has been introduced into population of cis conformers in the tripeptide Piv- Pro- C heterochiral diproline segments that have been previously Pro-Leu-OMe (6). In the homochiral segment Piv-Pro- C shown to facilitate the formation of b-hairpins, containing Pro-Leu-OMe (7)onlythecis form is observed with the b central two and three residue turns. NMR studies of the NMR evidence strongly supporting a type VIa -turn ? octapeptide Boc-Leu-Phe-Val-DPro-CPro-Leu-Phe-Val- conformation, stabilized by a 4 1 hydrogen bond OMe (1), Boc-Leu-Val-Val-DPro-CPro-Leu-Val-Val-OMe between the Piv (CO) and Leu (3) NH groups. The crystal CH,CH3 (2), and the nonapeptide sequence Boc-Leu-Phe- structure of the analog peptide 7a (Piv-Pro- Pro- Val-DPro-CPro-DAla-Leu-Phe-Val-OMe (3)established Leu-NHMe) confirms the cis peptide bond geometry for CH,CH3 well-registered b-hairpin structures in chloroform the Pro- Pro peptide bond, resulting in a type VIa b # solution, with the almost exclusive population of the trans -turn conformation.
    [Show full text]
  • Université Du Québec À Montréal
    UNIVERSITÉ DU QUÉBEC À MONTRÉAL CONVERSION CONFORMATIONNELLE SECONDAIRE ET QUATERNAIRE D'HORMONES PEPTIDIQUES: ÉQUILIBRE ENTRE FONCTION BIOLOGIQUE ET AUTO-ASSEMBLAGE PATHOLOGIQUE THÈSE PRÉSENTÉE COMME EXIGENCE PARTIELLE DU DOCTORAT EN BIOCHIMIE PAR NOÉ QUITTOT SEPTEMBRE 2020 UNIVERSITÉ DU QUÉBEC À MONTRÉAL Service des bibliothèques Avertissement La diffusion de cette thèse se fait dans le respect des droits de son auteur, qui a signé le formulaire Autorisation de reproduire et de diffuser un travail de recherche de cycles supérieurs (SDU-522 – Rév.10-2015). Cette autorisation stipule que «conformément à l’article 11 du Règlement no 8 des études de cycles supérieurs, [l’auteur] concède à l’Université du Québec à Montréal une licence non exclusive d’utilisation et de publication de la totalité ou d’une partie importante de [son] travail de recherche pour des fins pédagogiques et non commerciales. Plus précisément, [l’auteur] autorise l’Université du Québec à Montréal à reproduire, diffuser, prêter, distribuer ou vendre des copies de [son] travail de recherche à des fins non commerciales sur quelque support que ce soit, y compris l’Internet. Cette licence et cette autorisation n’entraînent pas une renonciation de [la] part [de l’auteur] à [ses] droits moraux ni à [ses] droits de propriété intellectuelle. Sauf entente contraire, [l’auteur] conserve la liberté de diffuser et de commercialiser ou non ce travail dont [il] possède un exemplaire.» REMERCIEMENTS Au Professeur Steve Bourgault, à qui je souhaite tout d’abord exprimer ma gratitude pour m’avoir accepté en tant qu’étudiant au doctorat au sein de son laboratoire. Merci d’avoir été un directeur de thèse présent et à l’écoute tout au long de mon doctorat.
    [Show full text]
  • Peptide Publications from Mimotopes Pty Ltd Or Collaborators
    Peptide Publications 1 PEPTIDE PUBLICATIONS 1. Peptide publications from Mimotopes Pty Ltd or Collaborators Thomas, D. A.; Francis, P.; Smith, C.; Ratcliffe, S.; Ede, N. J.; Kay, C.; Wayne, G.; Martin, S. L.; Moore, K.; Amour, A.; Hooper, N. M., A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics 2006, 6, (7), 2112-20. Ercole, F.; FitzGerald, M.; Perera, S.; Ede, N.; Riley, P.; Campbell, R., A combinatorial approach in designing hydrophilic surfaces for solid-phase peptide synthesis. J. Appl. Polym. Sci. 2003, 89, (12), 3371-3378. Khammanivong, V.; Liu, X. S.; Liu, W. J.; Rodda, S. J.; Leggatt, G. R.; Tindle, R. W.; Frazer, I. H.; Fernando, G. J., Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol. Cell Biol. 2003, 81, (1), 1-7. Nelson, P. N.; Westwood, O. M.; Soltys, A.; Jefferis, R.; Goodall, M.; Baumforth, K. R.; Frampton, G.; Tribbick, G.; Roden, D.; Hay, F. C., Characterisation of epitopes of pan- IgG/anti-G3m(u) and anti-Fc monoclonal antibodies. Immunol. Lett. 2003, 88, (1), 77-83. Takahashi, T.; Nagamiya, H.; Doi, T.; Griffiths, P. G.; Bray, A. M., Solid phase library synthesis of cyclic depsipeptides: aurilide and aurilide analogues. J. Comb. Chem. 2003, 5, (4), 414-428. Deliyannis, G.; Jackson, D. C.; Ede, N. J.; Zeng, W.; Hourdakis, I.; Sakabetis, E.; Brown, L. E., Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J. Virol. 2002, 76, (9), 4212-21. Ede, N.
    [Show full text]
  • Investigation of the Zinc Binding Region of Prothymosin-Alpha: a Spectroscopic and Thermodynamic Approach to Study Metal Binding in Intrinsically Disordered Proteins
    Investigation of the Zinc Binding Region of Prothymosin-alpha: A Spectroscopic and Thermodynamic Approach to Study Metal Binding in Intrinsically Disordered Proteins Abstract The goal of this study is to provide a deeper insight into how metals bind intrinsically disordered proteins (IDPs) by taking zinc binding to prothymosin-alpha as a case study. The involvement of metals in several diseases caused by (IDPs) has been noted long ago (Cu binding of α-synuclein in Parkinsons disease, prion aggregation due to Cu in madcow disease. etc.). However, there is still a lack of understanding of how metal binds IDPs. A deeper insight into metal binding by IDPs is essential for a full understanding of a proteome and to pave a way for drug development. Prothymosin-alpha (Protα) is an acidic, natively unfolded, and highly conserved protein located mostly in the nucleus of eukaryotic cells. It consists of 110 amino acids out of which 53 residues are aspartic (D) and glutamic (E) acids thus it is highly acidic. The exact biological role of the protein is unknown. However, it has been shown to be involved in cell proliferation, chromatin remodeling, antiapoptotic activity etc. One of the most interesting characteristics of Protα is its ability to bind metal cations like Ca2+, Mg2+, Mn2+, Zn2+, Al2+. In the background of all these cations, Protα selectively interacts with Zn2+ and undergoes a structural change plus the interactions of the protein with its binding partners are enhanced in the presence of Zn2+. These features underline the importance of Zn2+ binding in Protα. Very little information is available about Zn2+ binding to Protα.
    [Show full text]
  • Bachem ÂŒ Insights Into Peptide Chemistry Achievements by The
    874 CHIMIA 2013, 67, Nr. 12 PePtide Science in Switzerland doi:10.2533/chimia.2013.874 Chimia 67 (2013) 874–880 © Schweizerische Chemische Gesellschaft Bachem – Insights into Peptide Chemistry Achievements by the World’s Leading Independent Manufacturer of Peptides Monika Mergler, Günther Loidl, Martina Diekmann, and Fritz Dick* Abstract: The Swiss fine chemicals company Bachem, pioneer and specialist in the chemical synthesis of peptides, has also become an internationally leading manufacturer of peptide active pharmaceutical ingredients (APIs). In response to increasing demands in scale and purity, Bachem’s research efforts centered on the chemistry involved in solid-phase peptide synthesis and the production of the required amino acid derivatives with the aim of a continuous improvement of the technology. The resulting optimized protocols together with high-throughput equipment enabled us to manufacture long peptide APIs and, more recently, even pharma-grade glycoproteins in industrial scale. Keywords: Active pharmaceutical ingredients · Large-scale peptide manufacturing · Process development · Side reactions · Solid-phase peptide synthesis Introduction Bachem and is still in our portfolio of more Peptide Synthesis at Bachem than 50 generic APIs. More than 40 years of experience al- This achievement triggered a further The ‘classical’ solution synthesis still lows us to highlight research and develop- significant growth: Processes for manu- has its place at Bachem for manufactur- ment activities in the field of peptide chem- facturing of luteinizing hormone-releasing ing short peptides for research purposes istry by Bachem. Achievements in the field hormone (LHRH), LHRH agonists, and or, adhering to cGMP guidelines, for ge- of liquid- and solid-phase synthesis, with even large peptides such as salmon calci- neric APIs.
    [Show full text]
  • Chemical Methods for Peptide and Protein Production
    Molecules 2013, 18, 4373-4388; doi:10.3390/molecules18044373 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Chemical Methods for Peptide and Protein Production Saranya Chandrudu 1, Pavla Simerska 1,* and Istvan Toth 1,2 1 School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Qld 4072, Australia; E-Mails: [email protected] (S.C.); [email protected] (I.T.) 2 School of Pharmacy, The University of Queensland, St. Lucia, Qld 4072, Australia * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +61-7-3365-4636; Fax: +61-7-3365-4273. Received: 12 March 2013; in revised form: 28 March 2013 / Accepted: 9 April 2013 / Published: 12 April 2013 Abstract: Since the invention of solid phase synthetic methods by Merrifield in 1963, the number of research groups focusing on peptide synthesis has grown exponentially. However, the original step-by-step synthesis had limitations: the purity of the final product decreased with the number of coupling steps. After the development of Boc and Fmoc protecting groups, novel amino acid protecting groups and new techniques were introduced to provide high quality and quantity peptide products. Fragment condensation was a popular method for peptide production in the 1980s, but unfortunately the rate of racemization and reaction difficulties proved less than ideal. Kent and co-workers revolutionized peptide coupling by introducing the chemoselective reaction of unprotected peptides, called native chemical ligation. Subsequently, research has focused on the development of novel ligating techniques including the famous click reaction, ligation of peptide hydrazides, and the recently reported -ketoacid-hydroxylamine ligations with 5- oxaproline.
    [Show full text]
  • A Snake Toxin As a Theranostic Agent for the Type 2 Vasopressin Receptor
    A snake toxin as a theranostic agent for the type 2 vasopressin receptor Laura Droctové, Manon Lancien, Vu Long Tran, Michaël Susset, Benoit Jego, Frederic Theodoro, Pascal Kessler, Gilles Mourier, Philippe Robin, Sékou Siramakan Diarra, et al. To cite this version: Laura Droctové, Manon Lancien, Vu Long Tran, Michaël Susset, Benoit Jego, et al.. A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Theranostics, Ivyspring International Publisher, 2020. hal-03070378 HAL Id: hal-03070378 https://hal.archives-ouvertes.fr/hal-03070378 Submitted on 15 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Theranostics 2020, Vol. 10, Issue 25 11580 Ivyspring International Publisher Theranostics 2020; 10(25): 11580-11594. doi: 10.7150/thno.47485 Research Paper A snake toxin as a theranostic agent for the type 2 vasopressin receptor Laura Droctové1, Manon Lancien1, Vu Long Tran2, Michaël Susset1, Benoit Jego2, Frederic Theodoro3, Pascal Kessler1, Gilles Mourier1, Philippe Robin1, Sékou Siramakan Diarra4, Stefano Palea4, Adrien Flahault5, Amélia Chorfa6, Maithé Corbani6, Catherine Llorens-Cortes7, Bernard Mouillac6, Christiane Mendre6, Alain Pruvost3, Denis Servent1, Charles Truillet2, Nicolas Gilles1 1. Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, 91191 Gif-sur-Yvette, France.
    [Show full text]